País: Israel
Idioma: anglès
Font: Ministry of Health
ESTRIOL
PERRIGO ISRAEL AGENCIES LTD
G03CA04
CREAM
ESTRIOL 0.1 %
VAGINAL
Required
ORGANON (IRELAND) LTD, IRELAND
ESTRIOL
ESTRIOL
For the treatment of vulvo-vaginal complaints related to estrogen deficiency.
2014-10-31
نبصت نأ عــقوتملا نــم ،١٠٠٠ نــیب نــم ٧ :HRT نــلوانتت يـ ـتاوللا ءاــسنلا ىدــل .ةيومد ةرــثخب :نينس ٥ ةرتفلو ،طسوتملاب ،نهرمع نم تانیتسلا يف ءاسن ىلإ رظنلاب نأ عــقوتملا نــم ،١٠٠٠ نــیب نــم ٨ :HRT نــلوانتت ل يــتاوللا ءاــسنلا ىدــل .ةــيومد ةرــثخب نــبصت نبصت نأ عــقوتملا نم ،١٠٠٠ نــیب نم ١٧ :HRT نــلوانتت يـ ـتاوللا ءاــسنلا ىدــل .ةيومد ةرــثخب كيدل وأ ردــصلا يف ئــجافم ملأ ،لــجرلا يف مــلؤم خاــفتنإ نــم نــيناعت تــنك اذإ !لاحلا يــف بیبطلا يـ ـعجار ،سفنتلا يــف لكاــشم نم .كلذ لــعف كــنكمي هــنأب بــيبطلا كرــبخي نأ ىــلإ ن آ لاا دــعب HRT يلمعتــست لا .ةيومد ةرــثخ ثودــحل تاملع نوــكت نأ هذــه نأــش كــلذ يــف اــمب ،ىرــخأ ةــيودأ ً ارــخؤم تلمعتــسإ اذإ وأ نیلمعتــست تــنك اذإ ! بــیبطلل ِ كــحإ ،ةــیئاذغ تاــفاضإو ةــیتابن ةـ ـيودأ ،ةــیبط ةـ ـفصو نودــب ةــيودأ .كـ ـلذ نــع يـ ـلدیصلا وأ :ةيلاتلا ةيود أ لاا نم دحاو يأ نيلوانتت تنك اذإ يلديصلا وأ كبیبط يغلب .نيپيزامابراكو نيئوتناديه ،تاروتيبراب لثم – عرصلل ةيودأ .نيسيمافيرو نيڤلوفويسيرچ لثم – تاثولتلل ةيودأ .ريڤانيفلن وأ ريڤانوتير ،زنيريڤافيإ ،نيپاريڤن لثم – ةيسوريڤلا تاثولتلل ةيودأ – )موتاروفريپ موكيرپيه( St. John’s Wort ىلع ةيواحلا ةيتابنلا ت Llegiu el document complet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT OVESTIN 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1mg estriol in 1g cream For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Vaginal cream Homogeneous, smooth, white to nearly white mass of creamy consistency. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of vulvo-vaginal complaints related to estrogen deficiency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Ovestin cream is an estrogen-only product for intravaginal use. One applicator-dose (applicator filled to the red mark) is 0.5g Ovestin cream containing 0.5 mg estriol. _Adults and Elderly _ • Treatment of atrophic vaginitis For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. The usual dose for atrophic vaginitis associated with the menopause is one applicator-dose per day for 2 to 3 weeks. As maintenance dosage, one applicator-dose twice a week is recommended. Medication should be discontinued every 2 to 3 months for a period of 4 weeks to assess the necessity for further treatment. • Pre-surgery therapy One applicator-dose per day should begin 2 weeks before the operation. • Post-surgery therapy Following surgery a period of at least 2 weeks should be allowed before resuming therapy using one applicator-dose twice a week. 1 In women not taking HRT or women who switch from another continuous combined HRT product, treatment with Ovestin cream may be started on any day. Women who switch from cyclic HRT regimen should start Ovestin cream treatment one week after completion of the cycle. _Route of Administration _ Ovestin cream is administered intravaginally by means of a calibrated applicator. The following ‘Instructions for Use’ should be given to the patient and are included in the Patient Information Leaflet: How to Apply the Cream Use the applicator to apply the cream in the vagina. A good time to do this is before going to bed. Llegiu el document complet